These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1220 related articles for article (PubMed ID: 21392017)

  • 1. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone.
    Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM
    Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
    Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
    Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
    Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
    Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):460-7. PubMed ID: 23201472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
    Jansen EM; Hanks SG; Terry C; Akard LP; Thompson JM; Dugan MJ; Jansen J
    Transfusion; 2007 May; 47(5):817-23. PubMed ID: 17465946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity.
    Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J
    Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cultures to evaluate engraftment potential of CD34+ cells from peripheral blood after mobilization by chemotherapy with and without GM-CSF.
    Benboubker L; Domenech J; Linassier C; Desbois I; Delain M; Lamagnere JP; Colombat P; Binet C
    Exp Hematol; 1995 Dec; 23(14):1568-73. PubMed ID: 8542948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
    Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
    Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.